Product Information
HUMULIN R 500 UNIT/ML KWIKPEN is a brand product labeled by Eli Lilly and Company, priced at $91.6074 per ML under NDC 00002882427. Its NADAC has been published 529 times since Aug 17, 2016.
Strength
500 [iU]/mL
Manufacturer
Eli Lilly and CompanyNDC
00002882427
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN HUMANApproval Type
Biologic (BLA)
FDA Application
BLA018780On Market Since
12/29/2015
Pharmacological Classes
Price Statistics
The NADAC for HUMULIN R 500 UNIT/ML KWIKPEN has been published 529 times since Aug 17, 2016, and over the history we have for it it has risen 6.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $91.6074 per ML |
|---|---|
| All-time high | $92.4705 (Jun 14, 2017) |
| All-time low | $85.7678 (Sep 21, 2016) |
| 52-week high | $91.6884 |
| 52-week low | $91.6074 |
| Median price | $91.7749 |
| Average price | $91.3918 |
| Largest weekly change | +7.8% (May 10, 2017) |
| Weeks tracked | 529 |
| Tracking since | Aug 17, 2016 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 22% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Insulin human market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HUMULIN R 500 UNIT/ML KWIKPEN?
The current National Average Drug Acquisition Cost (NADAC) for HUMULIN R 500 UNIT/ML KWIKPEN, manufactured by Eli Lilly and Company, is $91.6074 per ML (NDC 00002882427), effective Sep 30, 2026.
How has the price of HUMULIN R 500 UNIT/ML KWIKPEN changed over time?
Over the history we have for it, the NADAC for HUMULIN R 500 UNIT/ML KWIKPEN has risen 6.3%. It has been tracked across 529 weekly CMS publications since Aug 17, 2016.
What are the highest and lowest recorded NADAC prices for HUMULIN R 500 UNIT/ML KWIKPEN?
Since Aug 17, 2016, the NADAC for HUMULIN R 500 UNIT/ML KWIKPEN has ranged from a low of $85.7678 (Sep 21, 2016) to a high of $92.4705 (Jun 14, 2017), with a median of $91.7749 per ML.
Are there cheaper alternatives to HUMULIN R 500 UNIT/ML KWIKPEN?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, HUMULIN R 500 UNIT/ML VIAL, is $71.1742 per ML — about 22% below HUMULIN R 500 UNIT/ML KWIKPEN.
Who manufactures HUMULIN R 500 UNIT/ML KWIKPEN?
HUMULIN R 500 UNIT/ML KWIKPEN (NDC 00002882427) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.